GlassScriptPhysician profile
Tzonko V Milev
NPI 1689644510
$4,158.03
in general payments reported to CMS, 2019-2025
24 companies · $58.16 in 2025
The $58.16 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $163 · 2021: $571 · 2022: $697 · 2023: $1,042 · 2024: $1,259 · 2025: $58.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,928 · Consulting Fee: $365 · Education: $66.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,928.49 |
| Consulting Fee | $365.00 |
| Education | $66.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $731.57 | 2019-2024 | Farxiga, Lokelma, Evusheld |
| Otsuka America Pharmaceutical, INC. | $460.77 | 2020-2024 | Jynarque |
| Akebia Therapeutics INC | $449.93 | 2019-2024 | Auryxia, Vafseo |
| Amgen INC. | $418.86 | 2019-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $348.70 | 2022-2024 | |
| Vifor Pharma, INC. | $289.09 | 2019-2023 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $243.00 | 2021-2024 | |
| Glaxosmithkline, LLC. | $220.05 | 2021-2023 | Benlysta |
| Mallinckrodt Hospital Products INC. | $198.11 | 2020-2024 | Acthar, Terlivaz |
| Opko Pharmaceuticals, LLC | $177.22 | 2019-2023 | Rayaldee |
| Fresenius USA Marketing, INC. | $133.67 | 2019-2024 | Velphoro |
| Novartis Pharmaceuticals Corporation | $85.52 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $84.40 | 2022-2024 | Lupkynis |
| Nxstage Medical, INC. | $69.90 | 2021 | |
| Ardelyx, INC. | $50.20 | 2024-2025 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $36.13 | 2022-2024 | |
| Daiichi Sankyo INC. | $33.43 | 2021-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.91 | 2024 | Jardiance |
| Baxter Healthcare | $24.51 | 2024 | Renal - Acute |
| Lilly USA, LLC | $17.43 | 2024 | Jardiance |
| Ani Pharmaceuticals, INC. | $15.65 | 2022 | |
| Horizon Therapeutics Plc | $14.17 | 2023 | Krystexxa |
| Novo Nordisk INC | $13.80 | 2024 | Rybelsus, Ozempic |
| Mallinckrodt Enterprises LLC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tzonko Milev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.